William Federici Increases Stake in Stevanato Group S.p.A.

William Federici, an insider at Stevanato Group S.p.A. (NYSE:STVN), recently bought 4,975 shares of the company on June 12, 2026. This transaction did not specify a price or total value. Shares of Stevanato Group traded at $18.39 on Friday, reflecting investor interest in the healthcare sector company.

Insider Buying and Selling at Stevanato Group S.p.A.

On June 12, 2026, William Federici acquired 4,975 shares, adding to the insider activity within Stevanato Group. This transaction was not part of a pre-planned trading program. Other insiders, including Marco Dal Lago, the Chief Financial Officer, also purchased shares on the same day, while several insiders sold shares on June 15, 2026, at an average price of $17.09.

Other Institutional Activity in Stevanato Group

Several institutional investors have adjusted their positions in Stevanato Group. Conestoga Capital Advisors, LLC increased its holdings by 602,050 shares, ending with 8,491,751 shares valued at approximately $116.76 million, marking a 7.6% increase. Meanwhile, Neuberger Berman Group LLC trimmed its stake by 312,219 shares, holding 4,475,492 shares worth about $61.54 million, a 6.5% decrease. T. Rowe Price Investment Management, Inc. reduced its position significantly by 698,724 shares, now holding 3,224,908 shares valued at roughly $44.34 million, reflecting a 17.8% decrease. Conversely, BAMCO Inc /NY/ bolstered its stake by 498,714 shares, totaling 2,500,438 shares valued at $34.38 million, a 24.9% increase.

Stevanato Group S.p.A. Stock Down 12.6%

Shares of Stevanato Group S.p.A. traded near $18.39 on Friday. The company, with a market capitalization of about $5.02 billion, has a P/E ratio of 31.71 and a forward P/E of 21.95, indicating investor expectations for growth. Stevanato's stock has ranged from a 52-week low of $12.89 to a high of $28.00. The stock's 50-day moving average is $17.39, while the 200-day moving average is $19.57. The company maintains a current ratio of 1.63 and a quick ratio of 1.11, with a debt-to-equity ratio of 29.43.

Recent Earnings

Stevanato Group reported revenues of approximately $1.20 billion, growing by 6.6% recently. The company achieved a net margin of 11.75% and a return on equity of 9.59%. Earnings per share stood at $0.58. The next earnings report is expected on May 7, 2026.

Dividend

Stevanato Group pays an annual dividend rate of $0.06, yielding 0.34%. The dividend payout ratio is 10.59%, highlighting a conservative approach to returning capital to shareholders.

Analysts Set New Price Targets

On June 16, 2026, TD Cowen initiated coverage of Stevanato Group with a "buy" rating and a price target of $25. Wolfe Research assumed coverage on June 2, 2026, also with a "buy" rating and a target of $21. The consensus among analysts is a "buy" recommendation, with a mean target price of $24.45 based on 10 analyst opinions.

About Stevanato Group S.p.A.

Stevanato Group S.p.A., headquartered in Piombino Dese, Italy, designs, produces, and distributes products for the biopharma and healthcare industries across various regions including Europe, the Americas, and Asia Pacific. Founded in 1949, the company operates through its Biopharmaceutical and Diagnostic Solutions and Engineering segments. It offers drug containment solutions, drug delivery systems, and provides contract development and manufacturing services. Stevanato Group employs approximately 6,010 people under the leadership of CEO Franco Stevanato.

Bottom Line

William Federici's recent purchase of shares in Stevanato Group S.p.A. adds to the notable insider activity at the company. Investors keep a close eye on such transactions for potential insights into the company's future prospects. As a reminder, insider transactions are disclosed after they occur and may not fully reflect current positions.